We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Testing Strips to Make Rapid Antigen Testing as Powerful as PCR Testing

By LabMedica International staff writers
Posted on 06 Mar 2024
Print article
Image: New test strips raise the game in gene-based diagnostics (Photo courtesy of 123RF)
Image: New test strips raise the game in gene-based diagnostics (Photo courtesy of 123RF)

During the onset of the pandemic, individuals experiencing symptoms had to endure lengthy queues for lab-based PCR testing and then wait around two days for the results, to confirm if they were infected with the COVID-19 virus. This process was not only inconvenient but also involved complex and costly logistics, contributing to testing delays and increasing the risk of spreading the disease. Now, a newly developed biosensing technology enables the creation of gene test strips that can match the quality of traditional lab-based tests.

The new technology developed by a team of biomedical engineers at UNSW Sydney (Sydney, Australia) offers test strips that are as accurate as lab-based PCR tests, with the added advantage of quick, on-site disease detection. Described by the researchers as having “PCR in your pocket,” this advancement holds potential for broad applications in biomedical and environmental diagnostics across various sectors, including food, agriculture, and biosafety management. The technology allows for the detection of specific gene sequences at room temperature, using test strips that resemble the familiar RAT Covid test, potentially eliminating the need for long queues at PCR testing centers and drastically reducing costs to a few dollars per test. The test strips could be instrumental in rapidly responding to new pathogens, identifying areas with high antibiotic resistance, or in conservation efforts for endangered species.

The process of achieving PCR-level accuracy with these new test strips involves the creation of minuscule DNA nano-circles, each containing a fragment of the target DNA, such as the COVID virus. These nano-circles, approximately 2 nanometres in size, are then combined with CRISPR/Cas proteins, which are programmed to interact specifically with the target pathogen's DNA. When these proteins encounter the target DNA, they cause the DNA nano-circles to linearize, creating an abundance of 'fake targets.' This method triggers a molecular chain reaction, resulting in a flood of these fake targets that are easily detectable by the test strips, even with minimal presence of the original gene target.

This technology has been demonstrated to accurately detect COVID-19 virus and Helicobacter bacteria, which are responsible for stomach ulcers. Potential applications of this biosensing method extend beyond health diagnostics to include biosecurity (detecting invasive marine species), environmental science (tracking threatened species through DNA testing of environmental samples), and even cancer diagnosis, as demonstrated by the team's successful detection of cancer mutations in clinical patient samples.

“We think we created a new benchmark in biosensing – our gene-based tests will be able to be performed anywhere, anytime, by virtually anyone,” said study author Dr. Fei Deng.

Related Links:
UNSW Sydney

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more